ArticleNature communications2021
Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Discovery of a Reversible Sub-Picomolar Thrombin Inhibitor Using DCC.Angewandte Chemie (International ed. in English) · 2026Article
- An Explainable Machine Learning-Based QSAR Framework for Predicting Thrombin Inhibitory Activity.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.Circulation research · 2026Article
- Production and functional characteristics of a novel hirudin variant with better anticoagulant activities than bivalirudin.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- The Interconnected World of Coagulation Factors, Platelets and Plasminogen: A Novel Perspective on Biosynthetic Regulation.Life (Basel, Switzerland) · 2025Review
- Prospection of Peptide Inhibitors of Thrombin from Diverse Origins Using a Machine Learning Pipeline.Bioengineering (Basel, Switzerland) · 2023Article
- Purification and characterization of thrombin from camel plasma: interaction with camel tick salivary gland thrombin inhibitor.Journal, genetic engineering & biotechnology · 2023Article
- Improving treatment for acute ischemic stroke-Clot busting innovation in the pipeline.Frontiers in medical technology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite their limitations, unfractionated heparin (UFH) and bivalirudin remain standard-of-care parenteral anticoagulants for percutaneous coronary intervention (PCI). We discovered novel direct thrombin inhibitors (DTIs) from tick salivary transcriptomes and optimised their pharmacologic activity. The most potent, ultravariegin, inhibits thrombin with a K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.